OncoSignal
Live from Open Targets Platform, fetched 2026-11-11 23:14 UTC. Every row links to its source record.

MUTYH mutY DNA glycosylase

ENSG00000132781 · protein coding · Open Targets profile

Involved in oxidative DNA damage repair. Initiates repair of A*oxoG to C*G by removing the inappropriately paired adenine base from the DNA backbone. Possesses both adenine and 2-OH-A DNA glycosylase activities. {ECO:0000269|PubMed:10684930, ECO:0000269|PubMed:20418187, ECO:0000269|PubMed:20848659, ECO:0000269|PubMed:25820570, ECO:0000269|PubMed:26694661}.

In 14 of 15 cancers, the evidence for MUTYH comes mainly from inherited variants

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751mutyh-associated polyposismutyh-associated polyposismutyh-associated polyposis: germline 0.95classic familial adenomatous polyposisclassic familial adenomatous polyposisclassic familial adenomatous polyposis: germline 0.95gastric cancergastric cancergastric cancer: somatic 0.68gastric cancer: germline 0.80colorectal cancercolorectal cancercolorectal cancer: germline 0.76colon carcinomacolon carcinomacolon carcinoma: germline 0.80hereditary neoplastic syndromehereditary neoplastic syndromehereditary neoplastic syndrome: germline 0.95breast carcinomabreast carcinomabreast carcinoma: somatic 0.46breast carcinoma: germline 0.83colorectal adenocarcinomacolorectal adenocarcinomacolorectal adenocarcinoma: somatic 0.61gastric neoplasmgastric neoplasmgastric neoplasm: germline 0.85pilomatrixomapilomatrixomapilomatrixoma: germline 0.84familial colorectal cancerfamilial colorectal cancerfamilial colorectal cancer: germline 0.81familial colorectal cancer type Xfamilial colorectal cancer type Xfamilial colorectal cancer type X: germline 0.65hereditary breast carcinomahereditary breast carcinomahereditary breast carcinoma: germline 0.77malignant colon neoplasmmalignant colon neoplasmmalignant colon neoplasm: germline 0.61classic or attenuated familial adenomat…classic or attenuated familial adenomatous polyposisclassic or attenuated familial adenomatous polyposis: germline 0.76

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

Small molecule
Structure with Ligand
PROTAC
Database Ubiquitination

gnomAD loss of function constraint: o/e 0.8778600096702576 (upper bound 1.080899953842163). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of MUTYH's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of MUTYH's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.